Effect of atorvastatin on inflammatory mediators in patients with chronic heart failure and cardiac function.doc

 PAGE \* MERGEFORMAT 8 Effect of atorvastatin on inflammatory mediators in patients with chronic heart failure and cardiac function [Abstract] Objective: To investigate the atorvastatin on inflammatory mediators in patients with chronic heart failure hs-CRP, IL-6 and cardiac function. Methods: 62 patients with severe chronic heart failure patients were randomly divided into 2 groups, control group, 29 patients with conventional treatment, 33 cases observed in the conventional therapy plus atorvastatin 20mg daily orally for 10 months. NYHA classification before and after treatment assessment and a heart ultrasound examination, serum samples were collected and measured separation of serum hs-CRP, IL-6 levels. Results: After 10 months of observation of patients IL-6, hs-CRP levels lower than the control group (P lt;0.05), compared with the control group observed cardiac function significantly improved NYHA classification (P lt; 0.01), LVEF and FS echocardiogram showed an increase (P lt;0.01), LVDD decreased (P lt;0.01). Conclusions: Atorvastatin can reduce hs-CRP in patients with heart failure, and IL-6 and improve cardiac function in chronic active role in treatment of heart failure. [Keywords:] atorvastatin; chronic heart failure; inflammatory mediators Although in recent years, chronic heart failure (CHF) basic research and clinical treatment has made great progress, but the CHF mortality remains high, at home and abroad a number of studies have shown that patients with heart failure was diagnosed from the moment, the annual mortality rate of about 20% to 40% [1]. There is evidence that neuroendocrine activation and excessive secretion of cytokines involved in the occurrence and development of chain of CHF, CHF patients with persistent immune activation, inflammatory mediators in serum hs-CRP, IL-6, IL -10, TNF-@ and so the level of increase. atorvastatin against the body through a variety of mechanisms of inflammation [2], from September 2006 to Septe